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The gene (pol) encoding the Epstein-Barr virus (EBV) DNA polymerase is a member of the "early" class of
viral genes which are expressed shortly after activation of latent virus infection. First, mRNA from the
EBV-producing cell line, B95-8, treated with 12-O-tetradecanoylphorbol-13-acetate and sodium butyrate to
induce lytic replication and expression of this gene was analyzed. Northern (RNA) analysis revealed a message
of 3.7 kb found only in induced cells. 5' mapping ofpol mRNA by Si nuclease and primer extension analyses
indicates that transcription initiates at tightly clustered sites within a G+C-rich region 126 bp upstream of the
open reading frame. The same initiation region was identified in two other EBV-infected cell lines, P3HR1 and
Raji, after induction. Second, a 1.29-kb genomic fragment containing this region, when cloned upstream of the
chloramphenicol acetyltransferase reporter gene, demonstrated promoter activity in lymphoid cells cotrans-
fected with pEBV-RZ, a genomic expression construct that includes genes for the EBV immediate-early
transactivator proteins, BZLF-1 and BRLF-1. Within the upstream 1.29-kb sequence, two regions of 140 bp
and 101 bp appear to be needed for promoter activity. These results demonstrate that unlike most EBV genes
studied thus far, the pol gene contains multiple transcriptional start sites. The upstream regulatory region of
the promoter for the pol gene does not contain canonical promoter elements such as TATA and CAAT boxes
and, furthermore, is not constitutively active but requires transactivation by two or more viral proteins.
Infection with the Epstein-Barr virus (EBV) results in
either latent or productive infection. In latent infection, the
episomal form of the genome and restricted expression of the
viral genes are the hallmarks. The episomes are replicated by
the host cell DNA polymerase, resulting in orderly duplica-
tion of limited copy numbers of episomes without viral
replication and without cellular destruction. In contrast, in
productive EBV infection, large numbers of linear genomes
are replicated and encapsidated, mediated by expression of
immediate-early, early, and late viral genes, which include a
virally encoded DNA polymerase and its cofactors. Thus,
there are fundamental differences between the virus-cell
relations in latent and productive infections.
In the latent state, restriction of viral gene expression
includes suppression of the expression of viral DNA poly-
merase, which has not been detected (17, 37, 39). However,
expression of the gene can be induced by nucleoside analogs
such as iododeoxyuridine, phorbol esters, and superinfec-
tion and other agents (12, 17, 26, 37, 41). The mechanism
whereby viral DNA polymerase expression is controlled and
induced is central to understanding not only how latency is
disrupted and replication is activated, but it is also relevant
to how latency is maintained. The regulation of expression at
the level of transcription of the EBV DNA polymerase gene,
clearly a crucial aspect of the interplay between productive
and latent infection, has not been examined.
The EBV DNA polymerase is distinguishable from host
cell a and a polymerase by its salt-stimulated activity and
sensitivity to inhibitors of viral DNA synthesis, such as
nucleoside and pyrophosphate analogs (11, 12); the latter
property is the basis for sensitivity of EBV replication to
several antiviral drugs. The coding sequence (the fifth left-
ward open reading frame [ORF] of the BamHI A fragment
[BALF-5]) for the polymerase has recently been cloned and
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expressed in vitro (29, 36) and in Escherichia coli (45a), and
the properties of the enzyme are under study. In the Raji cell
line, salt-stimulated DNA polymerase activity is not sponta-
neously expressed. However, after 12-O-tetradecanoylphor-
bol-13-acetate (TPA) exposure, such activity can be detected
(41). In virus-producing cell lines such as P3HR1 and B95-8,
salt-stimulated DNA polymerase activity is already present
at appreciable levels before stimulation with TPA. These
levels can be substantially increased by treatment with TPA
through the conversion of latently infected cells that com-
prise the majority of the population to virus-producing cells
(12, 35).
Most investigations of gene regulation in EBV have cen-
tered on maintenance of latency and disruption of this state
by the expression of immediate-early genes encoding
BZLF-1 (Z) and BRLF-1 (R) (9, 10, 20-22, 27, 48). However,
there has been no attention to understanding events govern-
ing the progression of the lytic cycle to the involvement of
the polymerase gene. In virus-producing cell lines, polymer-
ase activity and virus production are increased after stimu-
lation with TPA, induction by surface immunoglobulin
cross-linking, or treatment with various other viral inducers,
depending on the cell line (12, 37, 41, 47).
In this report, expression of this early gene is character-
ized by mapping transcriptional initiation and by analyzing
the promoter activity of the gene. The data indicate that
unlike most EBV genes studied thus far, this gene contains
multiple transcriptional start sites and that its promoter does
not contain a canonical TATA box. The promoter, while it is
constitutively inactive, can be transactivated in lymphoid
cells by cotransfection with a construct that expresses
immediate-early gene products.
MATERIALS AND METHODS
Cell lines. B95-8 (38) is an EBV-positive marmoset B-cell
line grown in RPMI medium supplemented with 8% fetal calf
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FIG. 1. Schematic diagram of the DNA pol gene and Northern blot (RNA) analysis. (A) B95-8 genome location ofpol ORF (BALF-5) in
BamHI I/A is, as shown, flanked by SphI sites at positions 153,176 and 157,118. The fragment SphI at position 153,176 to StuI at position
156,695 was subcloned into pGEM3Z and linearized with Hindlll to generate runoff antisensepol transcripts by using T7 RNA polymerase.
(B) The probe diagrammed in panel A was hybridized to RNA from B95-8 cells induced with TPA and sodium butyrate. Lanes: 1, 5 ,ug of
poly(A)+; 2, 20 kg of poly(A)-; 3, 20 kg of total RNA, induced with TPA; 4, 20 kug of total RNA, uninduced; 5, 5 kg of poly(A)+ from
EBV-negative Jurkat cells. Arrowheads indicate 28S and 18S rRNA positions.
serum. P3HR1 (21) and Raji (44) are EBV-positive cell lines
derived from Burkitt's lymphomas and grown in RPMI
medium supplemented with 10% fetal calf serum. Jurkat is
an EBV-negative T-cell line maintained in RPMI medium
supplemented with 10% fetal calf serum. All cells were
maintained at 37°C in a 5% CO2 environment.
Induction of virus replication. The EBV lytic cycle was
induced by incubating B95-8 cells with TPA and sodium
butyrate for 48 h at 30 ng/ml and 5 mM (final concentrations),
respectively. Virus production was monitored by indirect
immunofluorescence for EA/VCA antigens by using high-
titer nasopharyngeal carcinoma patients' sera and fluores-
cein isothiocyanate-conjugated goat antihuman antibody.
Transfections and chloramphenicol acetyltransferase (CAT)
assays. Plasmid DNA was amplified from E. coli and purified
over two sequential cesium chloride gradients. For each
sample, 10 p.g of reporter and 10 ,ug of transactivator plasmid
DNA were electroporated into 10' cells at 1,500 V (40), with
the University of Wisconsin Zapper electroporation unit.
Cells were suspended in 10 ml of RPMI 1640 medium
supplemented with 10% fetal calf serum and incubated for 48
h at 37°C in 5% CO2. Extracts of transfected cells were
prepared by washing cell pellets twice in phosphate-buffered
saline solution, suspending them in 200 p.l of 0.25 M Tris-
HCI (pH 7.5), and freeze-thawing four times. Reactions were
carried out by incubating each sample with acetyl coenzyme
A and [14C]chloramphenicol at 37°C for 1 h (18). Reaction
products were separated by thin-layer chromatography, vi-
sualized by autoradiography, and quantitated by scintillation
counting. Percent acetylation was calculated as the ratio of
acetylated reaction products to the entire sample.
RNA isolation and Northern analysis. Total cellular RNA
from B95-8, P3HR1, and Raji cells was prepared 48 h
postinduction, and polyadenylated RNA was selected (1,
45). For Northern (RNA) analysis, 20 ,ug of total cellular
RNA or 5 pg of poly(A)+ RNA was denatured for 15 min at
65°C in the presence of formaldehyde and resolved on a 1%
agarose gel containing 0.66 M formaldehyde, 20 mM 3-(N-
morpholino)propanesulfonic acid, 5 mM sodium acetate, and
1 mM EDTA. Following electrophoresis, RNA was blotted
onto nitrocellulose filters, fixed by heat, and prehybridized
for 2 h at 59°C in prehybridization solution containing 50%
formamide, 1Ox SSC (lx SSC is 0.15 M NaCl plus 0.015 M
sodium citrate), 50 mM sodium phosphate (pH 7.0), 2.5x
Denhardt's solution, and 200 ,ug of salmon-sperm DNA per
ml. Hybridization was performed in the same solution at
59°C. Filters were washed at 65°C in 0.1 x SSC-0.1% sodium
dodecyl sulfate and treated with RNase A (13).
Si nuclease and primer extension analyses. For Si nuclease
protection assays of viral RNA, mRNA was prepared, as
described above, from TPA-induced and uninduced B95-8,
P3HR1, and Raji cells. Si probes were prepared by subclon-
ing EBV fragment SphI (at position 153,176) to StuI (at
position 156,695) into phagemid pBS+ (Stratagene) and
generating single-stranded DNA template by using helper
phage M13K07. A 39-base 32P-end-labelled primer (positions
156,801 to 156,840) was annealed to the template and ex-
tended with Klenow enzyme. After digestion with SphI, the
strands were separated on a denaturing polyacrylamide-urea
gel, and the appropriate size band was recovered. Five
micrograms of poly(A)+ was hybridized for 12 h with 5 x 104
cpm of the end-labelled probe (see Fig. 2) in 30 pu1 of 40 mM
PIPES [piperazine-N-N'-bis(2-ethanesulfonic acid) (pH
6.4)]-1 mM EDTA (pH 8.0)-0.4 M NaCl-80% formamide at
45°C. Si digestion was carried out by addition of 800 U of S1
nuclease in 300 ,ul of 0.28 M NaCl-0.05 M sodium acetate
(pH 4.5)-4.5 mM ZnSO4-20 ,ug of single-stranded calf-
thymus DNA per ml. Reactions were terminated by addition
of 80 pul of a mixture containing 4 mM ammonium acetate
and 50 mM EDTA (pH 8.0). Products were resolved on 7 M
urea-6% polyacrylamide gels and visualized by autoradiog-
raphy.
For Si nuclease protection assays performed on CAT
RNA, an internally labelled single-stranded DNA probe
complementary to plasmid pPolCAT was made. Single-
stranded template DNA was prepared as described above
and annealed to a 20-base primer that hybridized from 133 to
153 bases downstream of the RNA start site region (see Fig.
5). The primer was extended and labelled with Klenow
enzyme and [32P]dCTP. After digestion with SphI, the probe
was isolated as described above. Polyadenylated RNA from
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FIG. 2. S1 nuclease and primer extension analyses of the 5' end of EBV DNApol mRNA. (A) For S1 analysis, the 32P-end-labelled probe
was annealed to 5 ,ug of poly(A)+ RNA isolated from B95-8, uninduced (lane 1) or induced (lane 2), or Jurkat cells (lane 3). (B) For primer
extension analysis, the 32P-end-labelled oligonucleotide was annealed to 5 ,ug of poly(A)+ RNA isolated from B95-8 cells, uninduced (lane 1)
or induced (lane 2), or Jurkat cells (lane 3). Hybridized mixtures were either treated with S1 nuclease or reverse transcribed with avian
myeloblastosis virus reverse transcriptase, and products were resolved as described in Materials and Methods. The sequence ladder was
generated by using the same oligonucleotide primer and single-stranded DNA from a genomic pol subclone shown in Fig. 1A to determine
precisely the site of transcription initiation. S1 probe (positions 156,801 to 157,118) and oligonucleotide primer (positions 156,801 to 156,840)
used in mapping are as diagrammed.
hybridized at 30°C to 105 cpm of the labelled probe. SI
digestion was carried out by addition of 100 U of Si nuclease
under conditions described above.
For primer extension analysis, 5 x 10' cpm of 32P-end-
labelled primer (see Fig. 2) was annealed as described above,
precipitated, and resuspended in 30 ,ul of reverse tran-
scriptase buffer containing 50 mM Tris (pH 7.6), 60 mM KCl,
10 mM MgCl2, and 1 mM dNTPs. Reactions were carried out
with 30 U of avian myeloblastosis virus reverse transcriptase
at 42°C for 1 h, and products were resolved as described for
Si analysis.
Plasmid constructs. pBS.CAT was constructed by isolating
the 1.7-kb BglII-BamHI CAT gene of pCAT3M (32) and
cloning it into the BamHI site of pBS+ (Stratagene). Subse-
quently, pPolCAT was constructed by isolating a 1.29-kb
BalI restriction fragment (EBV coordinates from positions
156,859 to 158,149) and cloning it into the HincIl site directly
upstream of CAT. Constructs containing deletions of this
fragment are described below.
RESULTS
Induction of EBV DNA polymerase expression in B95-8
cells. To optimize for EBV DNA polymerase expression,
EBV-producing B95-8 cells were induced with TPA and
sodium butyrate so that a high percentage of cells entered
the lytic phase. Virus production was monitored over the
course of 72 h by indirect immunofluorescence with the use
of sera which contained high titers of EBV antibodies from
patients with nasopharyngeal carcinoma. With this induction
method, the percentage of cells positive for replicative
antigens (EA/VCA) (30 to 35%) was greatest between 48 and
72 h (data not shown).
RNA from the 48-h point was used for a Northern analysis
performed with strand-specific 32P-labelled RNA probe an-
tisense to the polymerase ORF (4). This probe was prepared
from a genomic fragment encompassing the coding region of
the polymerase gene corresponding to the positions from
153,176 to 156,695 subcloned into pGem3Z (Promega) (Fig.
1A). The expected minimal size of the polymerase mRNA
according to the length of the coding region is -3 kb, and a
message of 3.7 kb was detected with this probe only in
induced cells (Fig. 1B, lanes 1 and 3). Although approxi-
mately 5% of uninduced B95-8 cells were spontaneously
producing virus, the sensitivity of the probe did not permit
detection of polymerase message in untreated cells. In this
induction, larger transcripts of 5, 8 and -11 kb were also
detected (Fig. 1, lane 1). These transcripts could represent
read-through messages from an upstream ORF, in particular,
BALF-4, which terminates 63 nucleotides downstream of
the first pol ATG, or unprocessed pol mRNA.
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FIG. 3. Comparison ofpol transcriptional initiation in P3HR1 and Raji cell lines. Si analysis was performed by using the same probe as
shown in Fig. 2 annealed to 5 ,g of poly(A)+ RNA isolated from B95-8 cells, induced (lane 1) or uninduced (lane 2); P3HR1 cells, induced
(lane 3) or uninduced (lane 4); Raji cells, induced (lane 5) or uninduced (lane 6); and Jurkat cells (lane 7). The sequence ladder was generated
as described in the legend to Fig. 2.
S1 nuclease and primer extension analyses of the 5' end of
the EBV DNA polymerase transcript. To map precisely the
transcriptional start sites of the polymerase gene, an S1
nuclease protection assay was performed. A 32P-end-la-
belled single-stranded DNA probe (coordinates from posi-
tions 156,801 to 157,118) antisense to polymerase mRNA
was synthesized and annealed to polyadenylated RNA from
induced cells at the 48-h point (Fig. 2). A sequence ladder
corresponding to the probe was used to identify the points of
discontinuity between probe and RNA. Protection of probe
was not detected with mRNA from uninduced B95-8 cells or
from Jurkat cells, an EBV-negative T-cell line (Fig. 2A,
lanes 1 and 3). Other Si analyses were performed with
longer probes extending into the ORF downstream of the
first in-frame ATG (coordinate at 156,746), all of which
identified the same tight cluster of start sites (data not
shown).
As a confirmation for the S1 nuclease analyses results,
primer extension analysis was performed with the same
end-labelled oligonucleotide (coordinates from positions
156,801 to 156,840) used to synthesize the S1 probe (Fig. 2).
As shown in the corresponding sequence ladder, the primer
extension results agreed with the S1 data, identifying the
identical transcriptional initiation region (Fig. 2B) and mak-
ing it unlikely that the Si nuclease assay was recognizing an
RNA splice junction.
The start sites in TPA-induced P3HR1 cells and Raji cells
were also determined by Si nuclease analyses by using the
same probe as that used for Fig. 2. The pol transcriptional
start sites in the two additional lines were essentially the
same as those in B95-8 cells in both this and the previous
analysis (Fig. 3).
Sequencing of cDNA clones generated from B95-8 TPA-
induced RNA as well as RNA-based polymerase chain
reaction analyses all further confirmed the same region of
clustered start sites (data not shown).
Thus, transcription of the EBV DNA polymerase gene
initiates 126 bp directly upstream of the ORF. The results
indicate that multiple start sites are used within a G+C-rich
region. The precise coordinates of these sites relative to the
B95-8 map are positions 156,872 to 156,877 (see Fig. 7).
Promoter activity for the EBV DNA polymerase gene. To
assay for promoter activity within this mapped region, a
1.29-kb genomic fragment corresponding to BalI sites
156,859 to 158,149 was cloned upstream of the CAT gene in
pBS+ and designated pPolCAT (Fig. 4). The EBV fragment
in the construct was sequenced and had neither a TATA box
nor a CAAT box; however, there appeared to be an SP1
motif (GGGCGG) within the transcriptional initiation region












FIG. 4. Promoter activity for the EBV DNA pol gene in Raji
cells. (A) Schematic representation of pPolCAT showing genomic
BalI fragment (coordinates 156,859 to 158,149) cloned upstream of
the CAT gene in pBSCAT. (B) pPolCAT was transfected into Raji
cells, a latently infected cell line, and assayed for CAT activity.
Lanes: 1, pPolCAT; 2, pPolCAT cotransfected with pEBV-RZ; 3,
positive-control plasmid, RSVCAT; 4, negative-control plasmid,
pBSCAT vector; 5, pBSCAT cotransfected with pEBV-RZ. The
percent conversion of chloramphenicol to its acetylated products is
indicated beneath each lane.
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FIG. 5. Confirmation of transcriptional start site in the pPolCAT reporter construct by S1 nuclease protection analysis. Raji cells were
transfected with pPolCAT and either pEBV-RZ (lane 1) or pHD101-3 (lane 2). Poly (A)' RNA was isolated from the transfected cells and
hybridized to the single-stranded DNA probe. The sequence ladder was synthesized by using the same oligonucleotide primer to generate the
single-stranded DNA probe from pPolCAT.
pPolCAT was transfected into latently infected Raji cells,
promoter activity could not be detected (Fig. 4, lane 1).
However, the promoter could be activated by cotransfection
with a genomic clone (pEBV-RZ) (lane 2) that expresses the
EBV immediate-early transactivators, Z and R (22). Thus,
the promoter was constitutively inactive in the Raji lym-
phoid cell line. This result is consistent with the latent nature
of this cell line and the undetectable polymerase activity in
uninduced cells (17, 41).
Si nuclease analysis of pPolCAT RNA from transfected Raji
cells. To confirm that the same sites for pol message initia-
tion were being used in the promoter construct, Si nuclease
analyses on CAT RNA derived from transient transfections
were performed. pPolCAT was cotransfected into Raji cells
with pEBV-RZ or its parent vector, pHD1013, which lacks
the genomic fragment encoding BZLF-1 and BRLF-1. Poly-
adenylated RNA was harvested 48 h posttransfection and
hybridized to a 32P-labelled single-stranded DNA probe (Fig.
5). After digestion with Si nuclease, a protected DNA
fragment of 153 bases was expected for the pol promoter
according to the previously determined RNA start site
region (Fig. 2 and 3). The results demonstrate that in
pPolCAT, pEBV-RZ-cotransfected Raji cells, the RNA start
sites are the same as those identified for EBV-infected cells.
Analyses of promoter activity of pPoICAT 5' deletions. To
begin to identify the elements responsible for promoter
activity, a series of nested 5' deletions of the pPolCAT
parent construct was made by restriction enzyme digestion
(Fig. 6). These constructs were transfected into Raji cells
either with or without the pEBV-RZ expression construct.
pPolCAT and pPolAHinc gave similar results, but the
pPolABgl construct disclosed a significant reduction in CAT
activity. Further deletions had little effect except for
pPolAAva, which was devoid of promoter activity despite
the fact that this construct preserves a Z-responsive element
as well as a possible SP1 consensus site (Fig. 7). These
results indicate that the 140-bp region between HincIl and
BglII (positions -853 to -713) and the 101-bp region be-
tween SphI and AvaI (-239 to -138) contain cis-acting
elements that contribute to promoter activity. Additional
deletions of the pPolCAT parent construct from the 3' end
removing the SphI-to-BalI fragment (-239 to +16) and the
AvaI-to-BalI fragment (-138 to +16) were made. These
deletions, which removed the mRNA initiation region, re-
sulted in total loss of promoter activity when cotransfected
into Raji cells with pEBV-RZ (data not shown).
DISCUSSION
In this report, the EBV DNA polymerase transcriptional
initiation region was mapped in TPA and sodium butyrate-
induced virus-producing B95-8 cells. With the use of S1
nuclease analysis and primer-extension assays, transcription
was shown to initiate from a small cluster of bases directly
upstream of the ORF. The region containing these start sites
spans map coordinates from positions 156,872 to 156,877 of
the B95-8 genome and lacks both a canonical TATA box and
a CAAT box, a characteristic associated with several house-
keeping genes (3, 50) and some nonhousekeeping genes (5,
23). Such genes may be regulated via a number of factors and
sequence motifs (2, 15, 46).
Furthermore, this region is G+C rich and contains a
potential SP1 site overlapping the most-5' RNA start site.
The proximity of this transcription factor binding site could
play a part in positioning transcriptional initiation, as with
the TATA-less promoter of the mouse thymidylate synthase
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FIG. 6. Schematic representation of deletion constructs of the pol promoter region and CAT activity in Raji cells. (A) Nested deletions
of the parent promoter construct, pPoICAT, extending from positions -1277 to +3 relative to the major RNA start site, were made by
digestion with the restriction enzymes shown and linked to the CAT gene in the promoterless vector pBSCAT. (B) Deletion constructs were
transfected into Raji cells, and CAT assay results are presented graphically. The percent conversion of chloramphenicol to its acetylated
products is indicated. Numbers above the bars represent fold transactivation of each construct with pEBV-RZ (RZ) over constitutive activity
with pHD1013 (C). The numbers shown represent the average fold increase from five experiments. Standard deviation is shown for each
sample.
gene (25). Transient assays with a plasmid construct con-
taining a 1.29-kb fragment cloned upstream of the CAT
reporter gene demonstrated promoter activity when cotrans-
fected into EBV-positive cells with a genomic clone that
expressed the EBV immediate-early transactivators, R and
Z. By using SI nuclease analysis, we mapped the pPolCAT
transcriptional start site region from these transient trans-
fections and have confirmed it to be the same as that of the
endogenous pol message. The same start sites are used in
two other EBV cell lines tested, P3HR1 and Raji. It will be
interesting to determine whether there are additional start
sites that can be distinguished kinetically, as in the case of
herpes simplex virus type 1 DNA pol transcription (6).
However, such studies are likely to be difficult with EBV
because they require a synchronous infection system. In
addition, removal of the start site region from promoter-CAT
constructs results in total loss of promoter activity and,
therefore, does not disclose alternate upstream start sites in
the constructs tested.
As EBV pol message is found only in cells actively
producing virus, it was necessary to induce an EBV cell line
to a high percentage of cells in the lytic cycle. This induction
was achieved with TPA and sodium butyrate treatment of
B95-8 cells. Northern analysis demonstrated a polymerase-
specific transcript of 3.7 kb along with other sequence-
related transcripts of 5, 8, and 11 kb detected with the
polymerase-specific probe. Since it is clear from the data






















































FIG. 7. Features of the DNA sequence in the 5' region of the EBV DNA polymerase gene. Sequence elements with potential relevance
for the expression ofpol are shown between positions -243 and +245. Potential binding sites for SP1 and ZRE are depicted. The predicted
hairpin, which includes the initiation codon for the ORF, is indicated by a horizontal line over the sequence. The polyadenylation signal which
is occluded for pol expression is boxed.
since functional protein is made from translation of in
vitro-made transcripts of the genomic fragment containing
the ORF (36), the large forms of polymerase-related tran-
scripts suggested that there may be 3' processing of RNA to
produce mature message. Indeed, examination of the EBV
B95-8 genomic sequence does not reveal a polyadenylation
signal within 3 kb downstream of the stop codon for the
ORF, indicating the likelihood of a splicing event. The
processing of the 3' end of this message is of some interest;
its role in regulation of expression is currently being inves-
tigated. More likely, the large transcripts represent read-
through messages transcribed from the upstream ORF,
BALF-4, which encodes glycoprotein B. A BALF-4-specific
probe detects 5.0-, 8.0-, and 11.0-kb transcripts from the
same induced RNA (data not shown). The existence of such
read-through transcripts has been proposed for the similarly
positioned glycoprotein B ORF of human cytomegalovirus
(30).
Although many enzymatic domains are conserved among
the EBV DNA polymerase-coding region and the homolo-
gous coding regions in other herpesviruses, the lack of a
TATA box in the noncoding regulatory region seems unique
to EBV among herpesviruses (30, 52). This characteristic is
evidently shared by a gene for another EBV replicative
enzyme, the DNase gene (8), which may suggest the possi-
bility of a mechanism for coordinate regulation of these
genes.
It is not obvious that Z and R act on the polymerase
promoter directly, as has been demonstrated for TATA-
containing EBV promoters. Different factors may be in-
volved in regulation. Examination of the pol promoter se-
quence does not reveal a canonical R-responsive element
(GTGCCN7GTGGAC or GTCCN6GTGGTG [19]) but does
reveal a canonical Z-responsive element 40 bp upstream of
the transcriptional start site region [TG(A/T)G(C/T)(C/A)A
(16, 33, 34, 49)]. However, this site does not fall within the
cis-acting regions defined so far that are important for
promoter activity (Fig. 6). An indication that this promoter
requires other transactivators in addition to R and Z is its
negligible activity when cDNA constructs that express R and
Z are cotransfected into EBV-negative cells. The R- and
Z-expressing genomic clone used in this work contains
portions of additional ORFs and is able to transactivate the
pol promoter in EBV-negative lymphoid cells (26a) (data not
shown). Another EBV gene product in the activation cas-
cade is BMLF-1, which is activated by R and Z (7). How-
ever, BMLF-1 is unlikely to act directly on the pol promoter
since it is a posttranscriptional transactivator (7, 28). The
role of BMLF-1 in this system is being investigated.
Yet another interesting feature is one common to the EBV
DNA polymerase and the herpes simplex virus DNA poly-
merase, namely, the potentially complicated secondary
structure in the 5' region of their transcripts. A AG of -71
kcal (-296 kJ)/mol has been reported for the herpes simplex
virus type lpol transcript from positions +155 to +308 (52),
and a similar stability of -60 kcal (-25 kJ)/mol is predicted
for the EBV pol transcript from positions +2 to +245
(relative to the transcriptional initiation region, Fig. 7) by
using the GCG FOLD program (14). Predicted hairpins of
similar stability have been shown to impair the translation of
thymidine kinase gene or human immunodeficiency virus
transcripts (31, 42, 43). The consequence of such secondary
structure in vivo is not known; however, synthetic tran-
scripts from genomic clones deleting most of this region are
more efficiently translated in rabbit reticulocyte lysates (29,
36). In addition, promoter constructs containing this region
WX'XM--
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show decreased CAT activity, possibly due to a translational
block (unpublished results).
Furthermore, 37 bp downstream of the AUG codon, there
is a functional polyadenylation signal used during late gene
expression of BALF-4 (Fig. 7). This signal must be ignored
during transcription of the pol gene itself. This inference is
suggested by the proximity of this signal to the 5' end of the
message. Occlusion of polyadenylation signals near the 5'
caps of spleen necrosis virus and human immunodeficiency
virus has been reported (24, 51); the signals function only
when placed more than 500 bp downstream of their promot-
ers. This observation indicates that not only transcriptional
mechanisms but also posttranscriptional and translational
mechanisms may govern expression of the EBV DNA poly-
merase.
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